Michael Enzo Furrow

Michael Enzo Furrow, Ph.D.


Partner, New York

Michael Furrow’s experience with and understanding of the challenges innate to discovery in the pharmaceutical and biotechnology fields fuels his passion to enforce and defend life sciences patents. He has represented innovators in high-stakes patent disputes both in Federal Court and before the U.S. Patent and Trademark Office concerning drugs or biologics for treating HIV/AIDS, Alzheimer’s disease, breast cancer, prostate cancer, bacterial infection, epilepsy, various endocrine, vascular and gastrointestinal diseases, and more, as well as laboratory tools such as gene sequencing techniques and genetically modified animals. Michael’s experience covers all aspects of life sciences innovation, including new chemical entities, salt forms, prodrugs, solid state forms, dosage forms, combination products, therapeutic methods, and laboratory techniques. Michael also provides opinions on infringement and validity issues, and conducts due diligence in connection with patent-related business transactions.

Michael joined Fitzpatrick directly out of law school. His scientific background is in the field of organic chemistry.


Recent Publications

Biosimilars and the Biologics Price Competition and Innovation Act (BPCIA)
Lexis Practice Advisor®
2018

Cost-Containment Strategies for Patentees in Litigation
Lexis Practice Advisor®
2018

Protecting Deuterated Drugs
Intellectual Property Magazine
2018

Strategies for Overcoming Early Litigation Challenges to Patent Eligibility
Lexis Practice Advisor®
2017

Scientific Publications

Pharmaceutical Patent Life-Cycle Management after KSR v. Teleflex
Food and Drug Law Journal
2008

A General Procedure for the Esterification of Carboxylic Acids with Diazoalkanes Generated In Situ by the Oxidation of N-tert-Butyldimethylsilylhydrazones with (Difluoroiodo)benzene
Journal of the American Chemical Society
2004

Practical Procedures for the Preparation of N-tert-Butyldimethylsilylhydrazones and Their Use in Modified Wolff-Kishner Reductions and in the Synthesis of Vinyl Halides and gem-Dihalides
Journal of the American Chemical Society
2004

Highly Selective Hydrolytic Kinetic Resolution of Terminal Epoxides Catalyzed by Chiral (salen) CoIII Complexes. Practical Synthesis of Enantioenriched Terminal Epoxides and 1,2-Diols
Journal of the American Chemical Society
2002

Practical Access to Highly Enantioenriched C-3 Building Blocks via Hydrolytic Kinetic Resolution
Journal of Organic Chemistry
1998

Case Highlight
Amgen et al. v. Teva Pharmaceuticals, et al.
D. Del. (2011)
Michael secured a victory in Hatch-Waxman litigation for Amgen and two other clients against two generic drug manufacturers. The district court ruled that Amgen’s drug Sensipar® for treating hyperparathyroud and carcinoma conditions were not invalid for anticipation, obviousness or double patenting, and had not been obtained through inequitable conduct before the U.S. Patent and Trademark Office.
Representative Matters
  • Salix Pharmaceuticals, Alfa Wassermann, Cedars-Sinai Medical Center, and Valeant Pharmaceuticals against a generic drug manufacturer in litigation on several families of patents covering the irritable bowel syndrome drug, Xifaxan®.  
  • Gilead Sciences and Emory University against various generic drug manufacturers in litigation on several families of patents covering the anti-HIV drugs Emtriva®, Viread®, Truvada® and Atripla®. 
  • AstraZeneca and KBI, Inc. against various generic drug manufacturers in litigation on various families of patents covering the proton pump inhibitor medicine Nexium® for gastric-acid related disorders. 
  • Amgen, NPS Pharmaceuticals, and Brigham & Women’s Hospital against various generic drug manufacturers in litigation on patents covering the calcimimetic Sensipar® for treating hyperparathyroid and carcinoma conditions. 
  • Novartis against Mylan in litigation on patents covering the breast cancer drug, Femara®, an aromatase inhibitor. 
  • Sanofi-Aventis and Bristol-Myers Squibb against various generic drug manufacturers in litigation and several reexamination proceedings on patents covering Plavix®, a leading anti-thrombotic agent.  
Events / Publications
News & Press